Shilpa Biologicals gets marketing authorization permission for Adalimumab 40 mg/0.4mL injection in prefilled syringe in India

Published On 2023-06-30 07:00 GMT   |   Update On 2023-06-30 07:00 GMT
Advertisement

KarnatakaShilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), has received the Marketing Authorization Permission for its Adalimumab 40 mg/0.4mL injection in prefilled syringe (PFS), a biosimilar of adalimumab higher concentration formulation (100mg/mL) in India.

This is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022.

Advertisement

Rheumatoid arthritis is a chronic disease that causes inflammation around the body and commonly presents with pain in the joints.

"This formulation will contribute to increased patient comfort based on reduced injection volume," the Company stated in a BSE filing.

"Shilpa Biologicals' extensive research and development efforts have resulted in the successful development of a high concentration biosimilar that matches the safety, purity, and potency profiles of the reference product," the Company further stated.

SBPL has been working on development of biosimilars catering to different therapeutic areas such as Immunology, Oncology, Ophthalmology, among which, Adalimumab is the first Biosimilar from Shilpa Biologicals Private Limited.

Read also: Shilpa Medicare Bengaluru facility gets registered with Ministry of Health, UAE

The product will be manufactured and supplied from the company's state-of-the-art biologics manufacturing unit located in Dharwad, Karnataka.

Medical Dialogues team had earlier reported that Shilpa Medicare had received final approval from the U.S Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Apremilast Tablets, 10 mg, 20 mg, and 30 mg.

Read also: Shilpa Medicare Psoriatic arthritis drug Apremilast gets USFDA okay

Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of API and Formulation globally in different regulated markets.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News